Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing ...

Viking Therapeutics stock is down 52% over the trailing-12-month period. However, many Wall Street analysts remain ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing contract, removing an overhang that has weighed on the stock for some time ...

Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I remain bullish on VKTX stock.

Currently trading with a volume of 1,145,610, the VKTX's price is down by -1.23%, now at $28.0. RSI readings suggest the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing study, which is evaluating the safety and efficacy of the oral formulation ...

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Viking Therapeutics, Inc. (VKTX).